丙型肝炎相关肝细胞癌肝移植术后的直接抗病毒治疗与肿瘤复发 - Suppr

Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.

作者信息

Yang Ju Dong, Aqel Bashar A, Pungpapong Surakit, Gores Gregory J, Roberts Lewis R, Leise Michael D

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, United States.

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Scottsdale, AZ, United States.

出版信息

J Hepatol. 2016 Oct;65(4):859-860. doi: 10.1016/j.jhep.2016.06.023. Epub 2016 Jul 5.

DOI:10.1016/j.jhep.2016.06.023

PMID:27392425

Abstract

摘要

相似文献

Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.

J Hepatol. 2016 Oct;65(4):859-860. doi: 10.1016/j.jhep.2016.06.023. Epub 2016 Jul 5.

Pro: Direct-acting antivirals are associated with occurrence and recurrence of hepatocellular carcinoma.

Liver Transpl. 2017 Dec;23(12):1593-1595. doi: 10.1002/lt.24960.

No Association Between Direct-Acting Antivirals and Hepatocellular Carcinoma Progression on the Waiting List: Time to Put This Controversy to Rest?

Liver Transpl. 2020 May;26(5):621-623. doi: 10.1002/lt.25746. Epub 2020 Apr 9.

Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.

J Hepatol. 2017 Dec;67(6):1355-1356. doi: 10.1016/j.jhep.2017.07.026. Epub 2017 Aug 10.

Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.

Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.

Hepatocellular carcinoma and direct-acting antivirals: A never ending story?

Liver Int. 2017 Jun;37(6):812-814. doi: 10.1111/liv.13421.

Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.

J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.

HCV therapy and risk of liver cancer recurrence: who to treat?

Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):392-393. doi: 10.1038/s41575-018-0018-5. Epub 2018 May 11.

Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus.

Liver Int. 2017 Jun;37(6):809-811. doi: 10.1111/liv.13422.

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.

PLoS One. 2018 Apr 16;13(4):e0194704. doi: 10.1371/journal.pone.0194704. eCollection 2018.

引用本文的文献

Frequency of Hepatocellular Carcinoma after Direct-acting Antiviral Therapy for Chronic Hepatitis C: A Prospective Follow-up.

Euroasian J Hepatogastroenterol. 2022 Jul-Dec;12(2):73-76. doi: 10.5005/jp-journals-10018-1383.

Mitochondria and Cancer Recurrence after Liver Transplantation-What Is the Benefit of Machine Perfusion?

Int J Mol Sci. 2022 Aug 28;23(17):9747. doi: 10.3390/ijms23179747.

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate.

World J Clin Cases. 2022 Feb 26;10(6):1764-1774. doi: 10.12998/wjcc.v10.i6.1764.

Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs.

Transl Cancer Res. 2019 Apr;8(Suppl 3):S223-S232. doi: 10.21037/tcr.2019.04.01.

Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study.

Clin Exp Hepatol. 2021 Mar;7(1):66-73. doi: 10.5114/ceh.2021.104397. Epub 2021 Mar 11.

Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.

Front Med. 2021 Apr;15(2):155-169. doi: 10.1007/s11684-021-0848-3. Epub 2021 Mar 23.

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C.

Transplant Direct. 2020 Dec 8;7(1):e635. doi: 10.1097/TXD.0000000000001049. eCollection 2021 Jan.

Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?

J Infect Dis. 2020 Nov 27;222(Suppl 9):S802-S813. doi: 10.1093/infdis/jiaa279.

Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy.

Gastrointest Tumors. 2020 Oct;7(4):134-143. doi: 10.1159/000510341. Epub 2020 Sep 14.

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.

Drug Des Devel Ther. 2020 Aug 25;14:3461-3468. doi: 10.2147/DDDT.S248850. eCollection 2020.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献